This post is presented by our media partner Grow Opportunity
View the full article here.
(Globe Newswire) Toronto — Avicanna Inc. a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the launch of RHO Phyto Micro Drop 100, a 10% CBD (THC free), proprietary oral formulation in Canada. RHO Phyto Micro Drop 100, is designed to deliver enhanced absorption of cannabinoids through an inverted emulsion technology. RHO Phyto Micro Drop 100 will be available to Canadian patients with medical authorization exclusively at the MyMedi.ca medical cannabiscare platform.
RHO Phyto Micro Drop 100 contains the same proprietary oral formulation as the product Trunerox™. Trunerox™ received drug approval in Colombia, earlier this year in February 2024, from the Colombian National Institute of Drug and Food Surveillance (El Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA). Trunerox™ is approved by INVIMA in Colombia as a drug for the treatment for severe seizures related to Lennox-Gastaut Syndrome and Dravet Syndrome. Trunerox™ has not been approved as a drug in Canada by Health Canada.
The company continues to support the advancement of research and development of plant-derived cannabinoid based products and continues to support the advancement of various scientific-medical initiatives. The company will be hosting its 4thMedical Symposium on cannabinoid-based medicine in the Canadian Healthcare System on May 13, 2024 for health care practitioners, scientists, researchers, and the medical community.
Advertisement
This post was originally published by our media partner here.
